
Owing to the high clinical failure rates, genetically variable tumor characteristics, and skyrocketing drug development costs, the era of traditional blockbuster oncology agents has come to an end.

Your AI-Trained Oncology Knowledge Connection!


Published: December 30th 2013 | Updated: